Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline



Boyd, Sara E ORCID: 0000-0001-9935-5263, Livermore, David M, Hooper, David C and Hope, William W ORCID: 0000-0001-6187-878X
(2020) Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64 (10). e00397-e00320.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Modern medicine is threatened by the global rise of antibiotic resistance, especially among Gram-negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and are increasingly disseminated worldwide, though particularly in Asia. Many MBL producers have multiple further drug resistances, leaving few obvious treatment options. Nonetheless, and more encouragingly, MBLs may be less effective agents of carbapenem resistance <i>in vivo</i>, under zinc limitation, than <i>in vitro</i> Owing to their unique structure and function and their diversity, MBLs pose a particular challenge for drug development. They evade all recently licensed β-lactam-β-lactamase inhibitor combinations, although several stable agents and inhibitor combinations are at various stages in the development pipeline. These potential therapies, along with the epidemiology of producers and current treatment options, are the focus of this review.

Item Type: Article
Uncontrolled Keywords: metallo-beta-lactamase, treatment, pharmacology, drug development, metalloenzymes
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 13 Jul 2021 08:26
Last Modified: 10 Feb 2024 03:08
DOI: 10.1128/AAC.00397-20
Open Access URL: https://ueaeprints.uea.ac.uk/id/eprint/76048/
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3129853